The American College of Cardiology (ACC) and American Heart Association (AHA) have jointly released the “Guideline for the Management of Patients With Acute Coronary Syndromes”. This comprehensive guideline integrates numerous recommendations from previously published guidelines, which have been revised with the latest evidence-based research. Additionally, new recommendations have been developed based on recent published data.

Acute Coronary Syndromes (ACS) are typically caused by the disruption (rupture or erosion) of an unstable coronary artery atherosclerotic plaque, leading to partial or complete coronary artery thrombosis and/or micro emboli. This results in reduced blood flow to the myocardium and subsequent myocardial ischemia. The focus of this guideline is on the acute management of ACS, encompassing unstable angina, NSTEMI, and STEMI, presumed to be caused by atherosclerotic plaque rupture or erosion and subsequent thrombosis. Patients with ACS face the highest risk of cardiovascular complications acutely, both before hospital presentation and during the early hospital phase. While appropriate management can mitigate this risk, patients remain at an elevated risk of recurrent cardiovascular events for several months to years following an ACS.

In this article, we will delve into the key takeaways and insights surrounding the guideline’s recommendations for ACS. Please note that this list does not encompass all major points. For a complete list of recommendations, refer to the summary located here or the full text guideline located here. 

Key Takeaways

Prehospital Care

  • Rapid prehospital care is essential in effectively managing patients with suspected ACS. Patients with suspected ACS should be transported to the emergency department (ED) by emergency medical services (EMS) rather than private vehicles to ensure they receive the necessary care.
  • In cases of suspected ACS, it is crucial for trained prehospital personnel to conduct a thorough assessment, including obtaining a focused history and physical examination, assessing vital signs, and obtaining at least one 12-lead ECG acquired and interpreted within 10 minutes of first medical contact. These electrocardiographic findings are vital in guiding the next steps in patient triage and treatment.
  • For patients presenting with suspected ST-elevation myocardial infarction (STEMI), it is recommended to promptly transport them via EMS to a hospital equipped to perform percutaneous coronary intervention (PCI) for primary PCI (PPCI). The goal is to achieve a first medical contact (FMC) to first device time of less than or equal to 90 minutes.

In-hospital Assessment With Confirmed or Suspected ACS

  • In patients presenting with suspected ACS, promptly measure cardiac Troponin (cTn) levels, preferably utilizing a high sensitivity cTn (hs-cTn) assay.
  • For patients with suspected ACS and an initial hs-cTn or cTn result that is inconclusive, it is recommended to schedule repeat measurements at specific time intervals following the initial sample collection (time zero). These intervals are advised to be 1 to 2 hours for hs-cTn assays and 3 to 6 hours for conventional cTn assays.

Oxygen Therapy

  • Supplemental oxygen has traditionally been a standard component of care for patients suspected of having ACS. However, there is a lack of evidence to support its clinical benefits in the absence of hypoxia. For patients diagnosed with ACS and confirmed hypoxia (oxygen saturation <90%), it is recommended to administer supplemental oxygen to increase oxygen saturations to ≥90%. This intervention is intended to improve myocardial oxygen supply and alleviate anginal symptoms.

Antiplatelet Therapy

  • Aspirin has long been recognized as an important component of antiplatelet therapy in the prevention of recurrent atherothrombotic events in ACS patients. Studies have shown that aspirin significantly decreases the incidence of vascular events following an AMI, and in secondary prevention trials involving post-MI patients, it has been shown to reduce the occurrence of vascular and coronary events, such as MI and stroke.
  • Traditionally, aspirin use after ACS was believed to be lifelong. However, a new approach involving the discontinuation of aspirin, rather than P2Y12 inhibitor discontinuation, may now be considered during the maintenance phase after 1 to 3 months in certain patients to minimize the risk of bleeding. This strategy represents a shift in the management of ACS patients and highlights the importance of individualized treatment plans based on patient characteristics and risk factors.

Lipid Management

  • For ACS patients, it is highly recommended to initiate high-intensity statin therapy in order to decrease the risk of Major Adverse Cardiovascular Events (MACE).
  • For patients with ACS who are already receiving the maximum tolerated dose of statin therapy and have a low-density lipoprotein (LDL) level of 70 mg/dL (1.8 mmol/L) or higher, it is advised to consider adding a nonstatin lipid-lowering agent to further reduce the risk of MACE.
  • In cases where patients with ACS are unable to tolerate statin therapy, it is recommended to utilize nonstatin lipid-lowering therapy to effectively lower LDL levels and decrease the risk of MACE.

Beta-Blocker Therapy

  • Beta blockers reduce myocardial oxygen demand by lowering heart rate, blood pressure, and myocardial contractility. 
  • For ACS patients who do not have contraindications, it is recommended to start oral beta-blocker therapy within 24 hours to decrease the risk of reinfarction and ventricular arrhythmias.

The authors note that guidelines are established to outline best practices for meeting the needs of patients in most situations, although they should not be seen as a replacement for clinical judgment. It is important to note that adherence to these recommendations can be improved through shared decision-making between healthcare practitioners and patients. This involves actively involving patients in the selection of interventions based on their individual values, preferences, and any associated conditions or comorbidities.

The purpose of this guideline is to improve patient outcomes by providing a comprehensive approach to diagnosing, managing, and treating ACS. We trust that you have found this Guideline Spotlight to be beneficial, and we strongly encourage you to review the complete guideline for a more in-depth understanding. Also, your thoughts and feedback are invaluable to us as we endeavor to provide informative and insightful content in our future spotlights. Thank you for being a valued member of our community!

Sign up for alerts and stay informed on the latest published guidelines and articles.

Copyright © 2025 Guideline Central, all rights reserved.